April, 2022
Site Specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios
October, 2021
XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer
April, 2021
XMT-1592, a Site-Specific Dolasynthen-Based NaPi2b-Targeted Antibody-Drug Conjugate for the Treatment of Ovarian Cancer and Lung Adenocarcinoma
June, 2020
Mersana’s Innovative ADC Platforms – World ADC Summit 2019
October 2019
Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform
April 2019
Discovery of the novel, homogeneous payload platform Dolasynthen for Antibody-Drug Conjugates
November 2018